Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
NCT00004086
Unknown
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver cancer killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2009
Locations: Garden State Cancer Center, Belleville, New Jersey
Conditions: Leukemia, Lymphoma
Register for Updates
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
NCT00004865
Completed
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab plus cisplatin in treating patients who have metastatic or recurrent cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2009
Locations: Cooper Cancer Institute, Camden, New Jersey +2 locations
Conditions: Head and Neck Cancer
Register for Updates
CPG 7909 Injection in Non-Small Cell Lung Cancer
NCT00070629
Completed
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every ot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2009
Locations: VA New Jersey Health Care System, East Orange, New Jersey
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
NCT00040625
Approved For Marketing
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2007
Locations: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Basking Ridge, New Jersey
Conditions: Mesothelioma
Register for Updates